Burden of oral anticoagulation in embolic stroke of undetermined source without atrial fibrillation
Klaus K Witte, Georgios Tsivgoulis, Matthew R Reynolds, Stelios I Tsintzos, Simon Eggington, Eleni Ismyrloglou, Julie Lyon, Marianne Huynh, Marta Egea, Bonnie de Brouwer, Paul D Ziegler, Noreli Franco, Rashmi Joglekar, Sarah C Rosemas, Shufeng Liu, Vincent Thijs
BMC CARDIOVASCULAR DISORDERS | BMC | Published : 2021
OBJECTIVE: Prevention of recurrent stroke in patients with embolic stroke of undetermined source (ESUS) is challenging. The advent of safer anticoagulation in the form of direct oral anticoagulants (DOACs) has prompted exploration of prophylactic anticoagulation for all ESUS patients, rather than anticoagulating just those with documented atrial fibrillation (AF). However, recent trials have failed to demonstrate a clinical benefit, while observing increased bleeding. We modeled the economic impact of anticoagulating ESUS patients without documented AF across multiple geographies. METHODS: CRYSTAL-AF trial data were used to assess ischaemic stroke event rates in ESUS patients confirmed AF-fr..View full abstract
CRYSTAL-AF and this cost-consequence analysis were funded by Medtronic, Inc.